Last reviewed · How we verify

Avodart — Competitive Intelligence Brief

Avodart (dutasteride) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-alpha-reductase inhibitor (dual). Area: Metabolic.

marketed 5-alpha-reductase inhibitor (dual) 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Avodart (dutasteride) — GSK (GlaxoSmithKline). Dual 5-alpha-reductase inhibitor (types I and II) that more completely suppresses DHT than finasteride for BPH treatment.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Avodart TARGET dutasteride GSK (GlaxoSmithKline) marketed 5-alpha-reductase inhibitor (dual) 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1 2001-11-20
Avodart Avodart GlaxoSmithKline marketed 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-alpha-reductase inhibitor (dual) class)

  1. GSK (GlaxoSmithKline) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avodart — Competitive Intelligence Brief. https://druglandscape.com/ci/dutasteride. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: